Topics
Latest
AI
Amazon
Image Credits:Craif / Craif
Apps
Biotech & Health
Climate
Image Credits:Craif / Craif
Cloud Computing
Department of Commerce
Crypto
endeavor
EVs
Fintech
Fundraising
Gadgets
bet on
Government & Policy
Hardware
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
Social
Space
startup
TikTok
conveyance
Venture
More from TechCrunch
effect
Startup Battlefield
StrictlyVC
newssheet
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
Cancer range as one of the top causal agency of destruction worldwide . The National Cancer Institutereported nearly 20 million Modern Cancer the Crab sheath and 9.7 million cancer - associate Death globally in 2022 , with projections testify a rise to 29.9 million newfangled cases by 2040 .
Craif , reel off from Nagoya University in Japan in 2018 , is using microRNA ( miRNA ) to develop an AI - powered early Crab signal detection software package , and it has call forth $ 22 million in Series C funding to expand further into the U.S. market and bolster its R&D.
Ryuichi Onose , co - founder and CEO of Craif , severalise TechCrunch in an interview that the company completed its Series C financial support rung with a evaluation of just under $ 100 million .
X&KSK , an existing investor , led the latest funding , which brings its total raised to $ 57 million to day of the month , along with the U.S.-based investor Unreasonable Group , its first investment in a Nipponese startup , TAUNS Laboratories , Daiwa House Industry , and Aozora Bank Group .
Craif ’s journey started when Onose see how deeply Crab affect his family , with both his grandparent being diagnose with the disease . These personal experiences have inspired a strong commitment to facilitate come up to the cancer event . Onose and Takao Yasui , an associate prof at Nagoya University , co - founded Craif just a month after they meet . Yasui had created a Modern method for early Crab detection using urinary biomarkers .
former detection of a treatable condition can be challenging , as traditional symptomatic method like blood tests can be invasive , causing some people to avoid regular screening , Onose say . In plus , modified admittance to medical quickness in certain area makes it challenging for individual to easy prevail cancer testing , according to Onose .
Craif aims to treat these gaps by providing a noninvasive urine - ground psychometric test that enables early Crab detection , even at a very former stage , like at Stage 1 .
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
“ The test can be deal from the puff of a patient ’s home and is powered by forward-looking microRNA depth psychology , make early detection more accessible and in force , ” Onose said . “ Our users are health - witting individuals who are implicated about cancer but find it challenge to trust to conventional screenings due to time , cost and accessibility constraints . ”
Several inauguration are create platform for other genus Cancer detection in the industriousness , likeGrail , Freenome , DELFI Diagnostics , andClearNote Health .
Craif differentiates itself by using microRNA as a biomarker instead of cfDNA ( cell - gratis DNA ) like most competitors and use urine .
Onose excuse that “ miRNA , which gained heightened realisation after being linked to the2024 Nobel Prize , is know for its thick involvement in Cancer the Crab biology even at the earliest level . Unlike cfDNA , miRNA is proactively secrete by former cancer cells , making it particularly suitable for former cancer detection . ”
Another unique aspect of its merchandise is its use of urine . Onose said urine is easy and noninvasive , put up many scientific and virtual benefits . It has few impurity than other sample , making the biomarker signals clearer , he added . This facilitate to decrease any measurement error , like those from haemolysis in bloodline , and save money on tests .
Craif ’s first ware , miSignal , a exam that detects the risk of seven different cancers ( pancreatic , colorectal , lung , stomach , esophagus breast , ovarian ) using urinary miRNA , is already sire gross in Japan . The intersection are distributed through clinics , drugstore , lineal - to - consumer sales , and corporate wellness program , providing a variety of tax revenue sources that can be expanded , fit in to the company ’s CEO .
“ We are partner with over 1,000 medical origination and about 600 drugstore in Japan , serving about 20,000 users . Our team consists of 73 dedicated employee , ” Onose narrate TechCrunch .
The revenue fashion model provide both single psychometric test and subscription software package for regular testing , with many drug user opt for subscription plans . It posted $ 5 million in revenue in 2024 and aim to bring forth $ 15 million by the end of this class , Onose evidence TechCrunch .
Craif destine to broaden the ambit of miSignal to include 10 dissimilar types of cancers this yr . Moreover , the startup is getting quick to apply its technology for the other detection of non - cancerous disease , such as neurodegenerative disorderliness like dementedness .
Craif has its R&D science lab in Irvine , California , and plans to open another office in San Diego to plow its business organisation operations .
The new funding will help the startup enter the U.S. market with its microRNA - based other cancer detection test , aiming to complete trial in the U.S. around 2029 and lodge for FDA approval .
It has already begun collecting pancreatic cancer samples in quislingism with 30 aesculapian institution across 15 U.S. states .
This fib was update to clear up Craif ’s plans for trials in the U.S.
